The Impact of COVID-19 On Comorbidities: A Review Of Recent Updates For Combating It.
The Impact of COVID-19 On Comorbidities: A Review Of Recent Updates For Combating It.
复制标题
DOI：
10.1016/j.sjbs.2022.02.006
复制
发表时间：
2022-05
影响因子：
4.4
通讯作者：
Anwar S
中科院分区：
文献类型：
--
作者：
Ahmad Malik J;Ahmed S;Shinde M;Almermesh MHS;Alghamdi S;Hussain A;Anwar S
SARS-CoV-2 can also affect organs other than the lungs, including the brain, heart, and gastrointestinal system. Patients with Cancer, HIV, COPD, neurological, and CVDs are more prone to the COVID-19 associated complications, leading to a drastic rise in morbidity and mortality. Elderly and pre-existing polypharmacy patients have worsened COVID-19 associated complications. When a person with comorbidity is infected with SARS-CoV-2, it becomes more dangerous, and managing these patients with adequate medical care is critical to their survival. A co-morbid person should adhere to preventive measures to reduce mortality, including regular handwashing with soap or using an alcohol-based hand sanitizer, minimizing in person contact and practicing social distance, wearing a face mask in public places, and avoiding going to public places unless essential are among the precautional measures. Coronavirus disease is caused by the SARS-CoV-2 virus. The virus first appeared in Wuhan (China) in December 2019 and has spread globally. Till now, it affected 269 million people with 5.3 million deaths in 224 countries and territories. With the emergence of variants like Omicron, the COVID-19 cases grew exponentially, with thousands of deaths. The general symptoms of COVID-19 include fever, sore throat, cough, lung infections, and, in severe cases, acute respiratory distress syndrome, sepsis, and death. SARS-CoV-2 predominantly affects the lung, but it can also affect other organs such as the brain, heart, and gastrointestinal system. It is observed that 75 % of hospitalized COVID-19 patients have at least one COVID-19 associated comorbidity. The most common reported comorbidities are hypertension, NDs, diabetes, cancer, endothelial dysfunction, and CVDs. Moreover, older and pre-existing polypharmacy patients have worsened COVID-19 associated complications. SARS-CoV-2 also results in the hypercoagulability issues like gangrene, stroke, pulmonary embolism, and other associated complications. This review aims to provide the latest information on the impact of the COVID-19 on pre-existing comorbidities such as CVDs, NDs, COPD, and other complications. This review will help us to understand the current scenario of COVID-19 and comorbidities; thus, it will play an important role in the management and decision-making efforts to tackle such complications.
登录
查看更多内容
影响因子：
4.7
作者：
Biswas S;Thakur V;Kaur P;Khan A;Kulshrestha S;Kumar P
通讯作者：
Kumar P
影响因子：
6.7
作者：
Albanghali M;Alghamdi S;Alzahrani M;Barakat B;Haseeb A;Malik JA;Ahmed S;Anwar S
通讯作者：
Anwar S
影响因子：
12.4
作者：
Dong, Xiang;Cao, Yi-yuan;Gao, Ya-dong
通讯作者：
Gao, Ya-dong
影响因子：
3.2
作者：
Bitencourt, Leticia;Pedrosa, Ana Luisa;Simoes e Silva, Ana Cristina
通讯作者：
Simoes e Silva, Ana Cristina
影响因子：
--
作者：
Epperla N;McKiernan F
通讯作者：
McKiernan F